• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
TREAT-NMD

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us

FSHD dataset

Home / What We Do / Core Datasets / FSHD dataset

The TREAT-NMD fascioscapulohumeral muscular dystrophy dataset serves as a vital resource for patient registries, facilitating the collection of comprehensive longitudinal data that captures the natural history of FSHD and informs the establishment of care standards. This dataset is designed to accommodate all registries collecting data on individuals with FSHD, including those reported by clinicians, patients, or through dual reporting.

Mandatory data items within the core dataset are essential components that registries must include in their data collection forms. This ensures the capability to store and provide the data, regardless of its availability for all individuals. While this represents a minimum core dataset, registries have the flexibility to collect additional items that align with their local interests or relevance.

Current Dataset

The latest version (v2.0) of the TREAT-NMD FSHD core dataset was developed to respond to recommendations from an ENMC workshop on FSHD data collection. The dataset includes:

46 unique data items
44 mandatory items for clinician-reported registries
44 mandatory items for patient-reported registries

Version 2 of the FSHD core dataset is available online.

Previous versions

Version 1 of the dataset has now been superseded by Version 2, but can be viewed here for information only.

How the dataset was created

Version 2 of the dataset was released in November 2021 and incorporated suggestions from the 225th ENMC Workshop held in Heemskerk, the Netherlands (2016 ENMC Workshop Report). A diverse group of 22 participants, including clinicians, researchers, patient advocates, and industry representatives from 11 different countries, convened to establish a global FSHD registry framework. The workshop’s central aim was to create a comprehensive dataset that could facilitate research and clinical trials for FSHD. Key processes involved analysing existing FSHD patient registries, refining the TREAT-NMD recommended dataset for FSHD, and fostering collaboration among research groups and patient advocacy organisations. The participants discussed diagnostic criteria, patient-reported outcomes, and genetic testing methods, ultimately refining the core dataset for international FSHD registries.

The dataset’s development was driven by the need for precise diagnosis, active patient involvement, and collaborative efforts among stakeholders, all geared toward supporting ongoing research and clinical trials in the field of FSHD.

Contact us

If you have further questions about the FSHD dataset or any questions regarding the implementation, please contact the registries team.

Registry Team Members

Neil Bennett

Neil Bennett

TGDOC and Communications Manager

Neil is an experienced science communicator; in the neuromuscular disease area, he has worked at Act...

Annie Poll

Annie Poll

Research Communications Lead, TREAT-NMD

Annie trained in several academic research laboratories at Newcastle University before taking on pos...

Farjana Ali

Farjana Ali

Datasets and Global Registries Platform Coordinator

Samantha Barker

Samantha Barker

Registry Network Administrator

Samantha (or Sammy) joined TREAT-NMD in July 2023. She has a background in administration and scienc...

Primary Sidebar

  • What We Do
  • Advisory Committee for Therapeutics
    • Advisory Committee for Therapeutics
    • Members of the Advisory Committee for Therapeutics
    • The Report
  • Global Registry Network
    • The Global Registry Network
    • Global Data systems Oversight Committee – TGDOC
    • Members of the Registry Network
  • Core Datasets
    • Core Datasets
    • DM dataset
    • DMD dataset
    • FSHD dataset
    • LGMD dataset
    • SMA dataset
  • Education
    • Education
    • Masterclasses
    • E-learning Platform
    • Endorsement of external programmes
  • Post-Marketing Surveillance
    • Post-Marketing Surveillance
    • STRIDE Registry

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter sign up

Connect

info@treat-nmd.com
TREAT NMD © 2023
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
    • Back
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
    • Back
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • The Report
      • Back
    • The Global Registry Network
      • Members of the Registry Network
      • Back
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
      • Back
    • Education
      • Masterclasses
      • E-learning Platform
      • Endorsement of External Programmes
      • Back
    • Post-Marketing Surveillance
    • Back
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
      • Back
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
        • Back
      • Back
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • FSHD Care
      • SMA Care
      • Back
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
        • Back
      • Back
    • Social and Ethical Issues
    • Back
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Back